Bicycle Therapeutics Limited

176 articles about Bicycle Therapeutics Limited

• Bicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  10/18/2021

  Bicycle Therapeutics plc today announced the closing on Friday, October 15, 2021 of its underwritten public offering of 3,726,852 American Depositary Shares (“ADSs”)

• Bicycle Therapeutics Announces Pricing of Upsized Public Offering of $175 Million of American Depositary Shares

  10/13/2021

  Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced the pricing of an underwritten public offering of 3,240,741 American Depositary Shares, each representing one ordinary share, at a price to the public of $54.00 per ADS, for gross proceeds of $175.0 million.

• Bicycle Therapeutics Announces Proposed $125,000,000 Public Offering of American Depositary Shares

  10/12/2021

  Bicycle Therapeutics plc today announced that it has commenced an underwritten public offering of $125,000,000 of American Depositary Shares (“ADSs”), each representing one ordinary share.

• Bicycle Therapeutics Announces Interim BT5528 Phase I Clinical Trial Results and Preliminary Results from Ongoing BT8009 Phase I Clinical Trial

  10/7/2021

  Bicycle Therapeutics plc (NASDAQ: BCYC), today provided a clinical update of its wholly-owned, next-generation Bicycle Toxin Conjugates (BTCs), reporting interim Phase I trial results for BT5528 and preliminary findings from the ongoing dose escalation portion of the BT8009 clinical trial.

• Bicycle Therapeutics to Present BT5528 Interim Phase I Data at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

  9/30/2021

  Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that interim Phase I results from its Phase I/II trial of BT5528, a second-generation Bicycle® Toxin Conjugate (BTC™) targeting EphA2, has been selected for a plenary oral presentation at the upcoming AACR-NCI-EORTC Virtual International Conference.

• Bicycle Therapeutics to Participate in Upcoming Investor Conferences

  9/1/2021

  Bicycle Therapeutics plc today announced that management will participate in the following investor conferences in September: Goldman Sachs Eleventh Annual Biotech Symposium on Tuesday, September 7, 2021

• Bicycle Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

  8/5/2021

  Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, reported financial results for the second quarter ended June 30, 2021 and provided recent corporate updates.

• Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology

  7/13/2021

  Ionis Pharmaceuticals, Inc. announced that it has entered into an exclusive licensing agreement with Bicycle Therapeutics plc to increase the delivery capabilities of Ionis' advanced LIgand Conjugated Antisense medicines.

• Bicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis to Develop Targeted Oligonucleotide Therapeutics

  7/13/2021

  Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced that Ionis Pharmaceuticals has exercised its option and entered into an exclusive worldwide license and collaboration agreement for tissue-targeted delivery of oligonucleotide therapeutics using Bicycles with high affinity to the transferrin receptor.

• Bicycle Therapeutics Announces Restrictions on Shareholder Attendance at Annual General Meeting to be Held on June 28, 2021

  6/15/2021

  Bicycle Therapeutics plc today announced an update regarding shareholder attendance at its 2021 Annual General Meeting (the “AGM”) to be held on June 28, 2021.

• Bicycle Therapeutics to Participate in Upcoming Virtual Investor Conferences

  5/27/2021

  Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that management will participate in the following virtual investor conferences in June: Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021; fireside chat at 11:00 a.m. ET

• Bicycle Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

  5/6/2021

  - BT7480, the lead Bicycle tumor-targeted immune cell agonist, presented at AACR Annual Meeting 2021 “New Drugs on the Horizon” session; remains on-track for 2H'21 clinical trial start - Achieved significant recent progress across pipeline of Bicycle ®-based therapies beyond oncology

• Bicycle Therapeutics Announces Presentations at the AACR Annual Meeting 2021

  4/10/2021

  Bicycle Therapeutics plc announced that for the first time, preclinical work describing the discovery of BT7480, a novel Nectin-4/CD137 tumor-targeted immune cell agonist, will be presented virtually in a “New Drugs on the Horizon” session at the American Association for Cancer Research Annual Meeting, taking place April 10-15, 2021.

• Bicycle Therapeutics Announces Significant Progress Across Multiple Therapeutic Programs Beyond Oncology

  3/30/2021

  - First milestone achieved in neuroscience collaboration with Dementia Discovery Fund and the Alzheimer’s Research UK Oxford Drug Discovery Institute - Significant advances made in the application of Bicycle technology against emerging antimicrobial and antiviral targets - Additional Bicycles identified through multiple development partnerships

• Bicycle Therapeutics Appoints Jose-Carlos Gutierrez-Ramos, Ph.D., to its Board of Directors

  3/18/2021

  Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of Jose-Carlos (“JC”) Gutierrez-Ramos, Ph.D., to its Board of Directors.

• Bicycle Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference

  3/11/2021

  Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ®) technology, today announced that management will participate in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference

• Bicycle Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

  3/11/2021

  - Significant progress achieved across pipeline of Bicycle ® Toxin Conjugates (BTCs™) and tumor targeted immune cell agonists (TICAs™) - Cash of $136.0 million at December 31, 2020 expected to provide financial runway through multiple clinical milestones - First clinical trial site outside of the United States opened in ongoing Phase I/II trial of BT8009

• Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data of Tumor-Targeted Immune Cell Agonists (TICAs™) in the Journal for ImmunoTherapy of Cancer

  1/26/2021

  Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data of Tumor-Targeted Immune Cell Agonists (TICAs™) in the Journal for ImmunoTherapy of Cancer

• Bicycle Therapeutics Announces Pipeline Progress Update - Jan 14, 2021

  1/14/2021

  BT7480 on track for Phase I trial start in 2H ’21; early immuno-oncology discovery has resulted in new programs targeting natural killer cells, which are now moving into lead optimization

• Bicycle Therapeutics to Present at the 2020 Piper Sandler Healthcare Conference

  11/24/2020

  Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that management will participate in a fireside chat at the 2020 Piper Sandler Healthcare Conference, which is scheduled to take place from December 1 – 3, 2020. The conference will be held in a virt